EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease

Carolin Kurz, Laura Stöckl, Isabelle Schrurs, Ivonne Suridjan, Selim Üstün Gürsel, Tobias Bittner, Alexander Jethwa, Robert Perneczky iD

Journal of Neurochemistry · 2023-04 · 165 (1) · 95-105

DOI: 10.1111/jnc.15757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 23.01.2023. Verfasst von Carolin Kurz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An unmet need exists for reliable plasma biomarkers of amyloid pathology, in the clinical laboratory setting, to streamline diagnosis of Alzheimer's disease (AD). For routine clinical use, a biomarker must provide robust and reliable results under pre‐analytical sample handling conditions. We investigated the impact of different pre‐analytical sample handling procedures on the levels of seven plasma biomarkers in development for potential routine use in AD. Using (1) fresh (never frozen) and (2) previously frozen plasma, we evaluated the effects of (A) storage time and temperature, (B) freeze/thaw (F/T) cycles, (C) anticoagulants, (D) tube transfer, and (E) plastic tube types. Blood samples were prospectively collected from patients with cognitive impairment undergoing investigation in a memory clinic. β‐amyloid 1–40 (Aβ40), β‐amyloid 1–42 (Aβ42), apolipoprotein E4, glial fibrillary acidic protein, neurofilament light chain, phosphorylated‐tau (phospho‐tau) 181, and phospho‐tau‐217 were measured using Elecsys ® plasma prototype immunoassays. Recovery signals for each plasma biomarker and sample handling parameter were calculated. For all plasma biomarkers measured, pre‐analytical effects were comparable between fresh (never frozen) and previously frozen samples. All plasma biomarkers tested were stable for ≤24 h at 4°C when stored as whole blood and ethylenediaminetetraacetic acid (EDTA) plasma. Recovery signals were acceptable for up to five tube transfers, or two F/T cycles, and in both polypropylene and low‐density polyethylene tubes. For all plasma biomarkers except Aβ42 and Aβ40, analyte levels were largely comparable between EDTA, lithium heparin, and sodium citrate tubes. Aβ42 and Aβ40 were most sensitive to pre‐analytical handling, and the effects could only be partially compensated by the Aβ42/Aβ40 ratio. We provide recommendations for an optimal sample handling protocol for analysis of plasma biomarkers for amyloid pathology AD, to improve the reproducibility of future studies on plasma biomarkers assays and for potential use in routine clinical practice. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansReproducibility of ResultsEdetic AcidAmyloid beta-PeptidesBiomarkersSpecimen Handlingtau ProteinsPeptide Fragments

Stichwörter der Autor:innen

Alzheimer's diseasebeta-amyloid (Aβ)glial fibrillary acidic protein (GFAP)neurofilament light chain (NFL)phosphorylated-tau (phospho-tau)pre-analytical stability

Substanzen

Edetic AcidAmyloid beta-PeptidesBiomarkerstau ProteinsPeptide Fragments

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Roche Diagnostics GmbH, Penzberg, Germany.
  • Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • German Center for Neurodegenerative Disorders (DZNE), Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

ORCID-Profile: Robert Perneczky

Zitieren

APA

Kurz, C., Stöckl, L., Schrurs, I., Suridjan, I., Gürsel, S. Ü., Bittner, T., Jethwa, A., & Perneczky, R. (2023). Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease. Journal of Neurochemistry, 165(1), 95-105. https://doi.org/10.1111/jnc.15757

Vancouver

Kurz C, Stöckl L, Schrurs I, Suridjan I, Gürsel SÜ, Bittner T, et al. Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease. Journal of Neurochemistry. 2023;165(1):95-105. doi:10.1111/jnc.15757

BibTeX
@article{Kurz2023,
  author = {Kurz, Carolin and Stöckl, Laura and Schrurs, Isabelle and Suridjan, Ivonne and Gürsel, Selim Üstün and Bittner, Tobias and Jethwa, Alexander and Perneczky, Robert},
  title = {Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease},
  journal = {Journal of Neurochemistry},
  year = {2023},
  volume = {165},
  number = {1},
  pages = {95--105},
  doi = {10.1111/jnc.15757}
}
Kostenlos starten →